Jefferies resumed coverage of Codexis with a rating of Buy and set a new price target of $5.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/19/2024 | Buy → Hold | The Benchmark Company | |
| 6/3/2024 | $5.00 | Buy | Jefferies |
| 5/30/2024 | $11.00 | Overweight | Cantor Fitzgerald |
| 2/29/2024 | Hold → Buy | The Benchmark Company | |
| 11/7/2023 | Buy → Hold | The Benchmark Company | |
| 8/7/2023 | $21.00 → $4.00 | Outperform → Market Perform | TD Cowen |
| 5/9/2023 | Buy → Neutral | H.C. Wainwright | |
| 3/31/2022 | $35.00 | Overweight | Piper Sandler |
Presentations by leading siRNA CDMOs, Bachem, Nitto Avecia, and ST Pharm, highlight performance and transferability of Codexis double-stranded RNA ligases Management to host conference call today at 8 am Eastern Time to discuss data REDWOOD CITY, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, presented data at the TIDES USA annual meeting in San Diego, California. Codexis' presentations showcased its proprietary ECO Synthesis platform's ability to support siRNA manufacturing by reducing purification costs, improving process performance, and demon
REDWOOD CITY, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the Company will attend the Jefferies Global Healthcare Conference, being held June 3-5, 2025, in New York, New York. Management will participate in a fireside chat on Wednesday, June 4, 2025, at 3:10 pm ET. A live webcast of the event will be available in the Investor Relations section of the Company's website, https://ir.codexis.com. A replay will be archived for 90 days following the event. About Codexis Codexis is a leading provider of enzymatic solutions for efficient and scalable therape
Secured first revenue-generating contract for ECO Synthesis™ manufacturing services Company reiterates full-year financial guidance Six presentations to feature the ECO Synthesis platform at upcoming TIDES USA annual meeting, including three from leading CDMO collaborators REDWOOD CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced financial results for the first quarter ended March 31, 2025, and provided a business update. "Codexis finished the first quarter with $60 million in cash, which remains on track to fund the company through cash flo